Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Limited Cardiac Biomarker Testing Decreases Health Care Costs

By LabMedica International staff writers
Posted on 15 Jul 2014
Two relatively simple tactics have been used to significantly reduce the number of unnecessary blood tests to assess symptoms of heart attack and chest pain and to achieve a large decrease in patient charges.

Cardiac biomarkers, such as the total creatine kinase (CK), the isoenzymes MB-fractions of the creatine phosphokinase enzyme (CK-MB), and troponin, are frequently ordered in the emergency department (ED) and inpatient units to evaluate patients suspected of having an acute coronary syndrome (ACS).

Scientists at Johns Hopkins Bayview Medical Center (Baltimore, MD, USA) designed and implemented a multimodal intervention to improve evidence-based ordering of cardiac biomarkers for the diagnosis of acute coronary syndrome (ACS). A total of 60,494 adult inpatient admissions from January 2009 through July 2011 (preintervention) and 24,341 admissions from November 2011 through October 2012 (postintervention) were included in the study.

The team targeted enabling factors by changing the computerized provider order entry system (Meditech; Westwood, MA, USA) by removing orders for CK and CK-MB from all standardized order sets and troponin orders from all order sets except two that are used for evaluation of new symptoms concerning ACS. They created a duplicate order pop-up warning when a troponin level was ordered sooner than six hours after another troponin level. They created pop-up warnings when a health provider attempted to order CK-MB or CK.

The primary outcome was percentage of patients with guideline-concordant ordering of cardiac biomarkers, defined as three or fewer troponin tests and zero CK-MB tests in patients without a diagnosis of ACS. Twelve months following the intervention, they estimated that guideline-concordant ordering of cardiac biomarkers increased from 57.1% to 95.5%, an absolute increase of 38.4%. They estimated that the intervention led to a 66% reduction in the number of tests ordered, and a decrease of USD 1.25 million in charges over the first year. At 12 months, there was an estimated absolute increase in incidence of primary diagnosis of ACS of 0.3 % compared with the expected baseline rate.

The authors concluded that by implementing a multimodal intervention they significantly increased guideline-concordant ordering of cardiac biomarker testing, leading to substantial reductions in tests ordered without impacting diagnostic yield. A trial of this approach at other institutions and for other diagnostic tests is warranted and if successful, would represent a framework for eliminating wasteful diagnostic testing.

Marc R. Larochelle, MD, the lead author of the study, said, “Through review of available evidence and reflection on our own practice, I believe we can proactively identify many practices that may be unnecessary and wasteful. We have demonstrated proof of concept that doctors can be leaders in delivering improved value for our patients and health care systems.” The study was published on June 28, 2014, in the Journal of General Internal Medicine.

Related Links:

Johns Hopkins Bayview Medical Center 
Meditech 



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Auto Clinical Chemistry Analyzer
cobas c 703
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.